Skip to main content
HomeShareholder information
Business man

Shareholders

Investor news

OSE Notice
Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II
Oslo, Norway
14 August 2026
PRESS-RELEASE
Cost neutrality of BLC versus WLC in a real-world setting demonstrated by new OPTUM study in the U.S.
Oslo, Norway
11 August 2026
OSE Notice
Photocure ASA: Notification of primary insider transactions
Oslo, Norway
7 August 2026
OSE Notice
Photocure ASA - Share option grant to members of the board of directors
Oslo, Norway
7 August 2026
OSE Notice
Photocure ASA: Asieris counterclaim on milestone payment arbitration
Oslo, Norway
4 August 2026
OSE Notice
Photocure ASA - Share option grant
Oslo, Norway
29 July 2026
OSE Notice
Photocure ASA: Results for the second quarter of 2026
Oslo, Norway
29 July 2026
NEWS POST
Photocure initiates arbitration in partial milestone payment case with Asieris Pharmaceuticals
Oslo, Norway
23 July 2026
PRESS-RELEASE
Photocure ASA: Invitation to presentation of second quarter 2026 financial results
Oslo, Norway
22 July 2026
OSE Notice
Photocure ASA - Share option grant
Oslo, Norway
14 July 2026
OSE Notice
Photocure ASA – CFO transition
Oslo, Norway
30 June 2026
OSE Notice
Photocure ASA: Annual general meeting held
Oslo, Norway
26 June 2026
PRESS-RELEASE
Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer
Oslo, Norway
8 June 2026
NEWS POST
First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions Completes First Import Shipment in China, with the First Global Prescription Issued in Beijing on the Same Day
Oslo, Norway
5 June 2026
OSE Notice
Photocure ASA - Notice of the Annual General Meeting 26 June 2026
Oslo, Norway
5 June 2026
OSE Notice
Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics
Oslo, Norway
4 June 2026